Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTIMISE-CKD CEE: A Multinational, Observational, Secondary Data Study Describing Management and Treatment With Dapagliflozin in Routine Clinical Practice Among Patients With Chronic Kidney Disease in Central Eastern Europe

NCT06203704 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06203704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06203704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTIMISE-CKD CEE: A Multinational, Observational, Secondary Data Study Describing Management and Treatment With Dapagliflozin in Routine Clinical Practice Among Patients With Chronic Kidney Disease in Central Eastern Europe
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
December 20, 2023
Completion date
September 30, 2025
Enrollment
1,086 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease (ckd)